European Union (Withdrawal) Bill

Lord Walney Excerpts

Committee: 7th sitting: House of Commons
Wednesday 13th December 2017 Commons Chamber

[Dr Whitford]

Okay, I am just going to move swiftly on. It was a speech, so my hon. Friend has had his chance to get that in.

There are multiple agencies that are important for the nations across the UK, but my particular interest is of course health. We know that the European Medicines Agency is moving to Amsterdam, but the much bigger issue is the UK coming out of the European Medicines Agency. This is a body that has massively reduced bureaucracy, streamlined the launch of new drugs and meant that the pharmaceutical industry has to go through only one registration process for 500 million people. That is why drugs are launched in Europe at much the same time as America and about a year before Canada and Australia. Given some of what is going on in NHS England—including the budget impact assessment, which can allow expensive drugs to be delayed for three years—what I am hearing from those in the pharmaceutical industry is that they see the UK as a hostile market and that they may not come six months later or a year later. It may take longer than that because they only see the point in paying the extra cost to register when they have a chance of their drug being used in the NHS.

[John Woodcock (Barrow and Furness) (Lab/Co-op)]

The hon. Lady is making an important point. Is she also mindful of the fact that, at a critical time for the future of the pharmaceuticals industry, there is currently no certainty even on cross-border production, which many of our companies are involved in, including GlaxoSmithKline in my constituency?

[Dr Whitford]

I agree. Processes such as quality control, batch certification and lot release must take place in the EU. Several centres in Scotland and, indeed, throughout the United Kingdom will have to move.